Cisplatin
Orphan DrugFDA Approved
Contents
Description
Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, inhibiting DNA replication and transcription. It has orphan drug designation for treatment of rare malignancies including pulmonary blastoma. The drug is typically used in combination chemotherapy regimens for various solid tumors.
Indications & Therapeutic Use
Testicular cancer, ovarian cancer, bladder cancer, lung cancer, pulmonary blastoma
Linked Diseases:
pulmonary blastoma
D018202
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Cisplatin — GNH India
94 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Cisplatin
EU
Cisplatin "ebewe"
EU
Cisplatin Accord
EU
Cisplatin Accord Healthcare
EU
Cisplatin Accord Healthcare Ireland
EU
Cisplatin Amarox
EU
Cisplatin Dawa
EU
Cisplatin Ebewe
EU
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Cisplatin
| Generic Name | Cisplatin |
| Brands | 1 brand available |
| Active Ingredient | Cisplatin |
| Drug Class | Testicular cancer |
| Manufacturer | Bristol-Myers Squibb |
| Dosage Forms | IV infusion 1mg/mL |
| Medical Code | L01XA01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00003299 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes